BRIEF-Regeneron Announces FDA Acceptance Of SBLA Filing For 12-Week Dosing Of Eylea(Aflibercept) Injection For Patients With Wet AMD
Dec 11 (Reuters) - Regeneron Pharmaceuticals Inc:
* REGENERON ANNOUNCES FDA ACCEPTANCE OF SBLA FILING FOR 12-WEEK DOSING OF EYLEA® (AFLIBERCEPT) INJECTION FOR PATIENTS WITH WET AMD
* REGENERON PHARMACEUTICALS - UNDER PDUFA, GOAL FOR STANDARD REVIEW OF AN SBLA IS TEN MONTHS FROM SUBMISSION FOR A TARGET ACTION DATE OF AUGUST 11, 2018 Source text for Eikon: Further company coverage: